New Performance Data Shows Why Pharma Is Reallocating Spend Toward Direct-to-Patient Care

New Performance Data Shows Why Pharma Is Reallocating Spend Toward Direct-to-Patient Care Pharmaceutical brands are increasingly shifting investment toward direct-to-patient (DTP) care models as a response to measurable performance. New data from ixlayer highlights how access-enabled DTP programs are accelerating time to care and converting patient demand into treatment. Across active ixlayer-powered programs, 85% of […] The post New Performance Data Shows Why Pharma Is Reallocating Spend Toward Direct-to-Patient Care appeared first on ixlayer .